Sunshine Biopharma, Inc.
SBFM Healthcare Drug Manufacturers Specialty & Generic
Sunshine Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.3 million, up 4.11% from fiscal 2024. In the quarter to June 2026, revenue fell 1.56%, EPS grew 70.5% and free cash flow grew 49.4%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow SBFM
Sunshine Biopharma, Inc. (SBFM) EV/Sales
As of 16 October 2026, Sunshine Biopharma, Inc. (SBFM) trades at a EV/Sales of −0.3×. Over the past ten years it has ranged from −67.7× (September 2022) to 45,704× (July 2020); the current reading is higher than 15% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.7× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.1× | — |
| FY2024 | −0.2× | — |
| FY2023 | −0.3× | — |
| FY2022 | −1.8× | — |
| FY2021 | 102× | 16.37% |
| FY2020 | 87.4× | (89.92%) |
| FY2019 | 867× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.3× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | −0.1× | — |
| Sep 2025 | 0.0× | — |
| 27 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SXTC China SXT Pharmaceuticals, Inc. compare | −5.9× |
| SBFM Sunshine Biopharma, Inc. | −0.3× |
| LSDIF Lucy Scientific Discovery Inc. compare | n/m |
| AKAN Akanda Corp. compare | n/m |
| PRFX PainReform Ltd. compare | n/m |
| IMCC IM Cannabis Corp. compare | 0.0× |
| PTPI Petros Pharmaceuticals, Inc. compare | 0.4× |
| NEPTF Neptune Wellness Solutions Inc. compare | 1.1× |
| BTAIQ BioXcel Therapeutics, Inc. compare | 228× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)